## **ASSIGNMENT**

WHEREAS, I, Samuel Rose M.D., the undersigned, being a citizen of Australia and a resident of 4 Commodore Drive, Apartment D-435, Emeryville, California 94608, have invented prior to January 12, 2000, the new and useful improvements and the inventions therein contained, which are listed on Schedule A attached hereto;

WHEREAS, the new and useful improvements and the inventions therein contained, which are listed on Schedule A, have <u>not</u> been disclosed, published, or set forth in any patent application or issued patent by the undersigned;

WHEREAS, Oncologic, Inc., a company organized and existing under and by virtue of the laws of the State of California, having a principal place of business at 3065 Richmond Parkway, Suite 117, Richmond, California 94806, is desirous of acquiring the entire right, title, and interest in and to the improvements and the inventions contained therein, which are listed on Schedule A, and any Letters Patents that may be issued upon said improvements therein contained;

NOW, THEREFORE, for and in consideration of the sum of One Dollar (\$1.00) lawful money of the United States and other valuable considerations, to me in hand paid, the receipt and sufficiency whereof is hereby acknowledged, I, the said Samuel Rose, have sold, assigned, and transferred and do hereby sell, assign, and transfer unto the said Oncologic, Inc., its successors and assigns, the entire right, title, and interest in and to the improvements and the inventions therein contained (collectively referred to as "the Inventions"), which are listed on Schedule A, including the right to apply for any Letters Patent in the United States America and in any and all foreign countries on said Inventions, and any and all other applications for Letters Patents on said Inventions, in whatsoever countries, including all divisional, renewal, substitute, continuation, and Convention applications, based in whole or in part upon said Inventions or upon said applications, and any and all Letters Patents that may issue thereon in the United States and in foreign countries, and any and all reissues, continuations of Letters Patents granted for said Inventions, or upon said applications, to the full end of the term or terms for which any and all of said Letters Patents may be issued, and every priority right that is or may be predicated upon or arise from said Inventions, said applications and said Letters Patents, the same to be held and enjoyed by the said Oncologic, Inc., its successors and assigns, the same as it would have been held and enjoyed by me if this assignment and sale had not been made.

And I hereby authorize the said Oncologic, Inc., to file patent applications in any or all countries on any or all of said Inventions in my name or in the name of the said Oncologic, Inc., or otherwise as the said Oncologic, Inc., may deem advisable, under the International Convention or otherwise.

And I hereby authorize the Commissioner of Patent of the United States and the empowered officials of all other governments to issue or transfer all said Letters Patents to the said Oncologic, Inc., as assignce of the entire right, title, and interest therein or otherwise as the said Oncologic, Inc., may direct, in accordance with this instrument of assignment.

I hereby represent and warrant that there are no rights or interests outstanding inconsistent with the rights and interests granted herein and that I will not execute any instrument or grant, transferring any rights and interests inconsistent with the rights and interests granted herein, and that I will not execute any instrument or grant, transferring any rights or interest inconsistent therewith, and I, the said Samuel Rose, M.D., bind myself and my heirs, executors, administrators, and legal representatives, as the case may be, to execute and deliver to the said Oncologic, Inc., its successors and assigns, any further documents or instruments and do any and all further acts that may be deemed necessary by the said Oncologic, Inc., its successors and assigns, to file applications for said Inventions in any country where it may elect to file such applications, and that may be necessary to vest in the said Oncologic, Inc., its successors and assigns, the title herein conveyed or intended so to be, and to enable such title to be recorded in the United States and foreign countries where such application or applications may be filed.

And I further covenant and agree, in consideration of the premises, that I, my executors, and my administrators, will at any time upon request, communicate to the said Oncologic, Inc., its successors and assigns, any facts relating to the said Inventions and improvements and the history thereof, known to me or to my executors and administrators, and that I will testify as to the same in any interference or other litigation when requested to do so by the said Oncologic, Inc., its successors and assigns.

IN TESTIMONY WHEREOF, I have hereunto set my hand and seal this 2 day of December, 2000.

STATE OF California ) SS:

On this the day of the

VOTARY PUBLIC

NOTARIAL SEAL



## SCHEDULE A

- 1. U.S. Patent No. 5,816,259, issued 10/06/98 in SN 08/782,380, filed 01/13/97, for "A Method For The Diagnosis And Treatment Of Cancer By The Accumulation Of Radioactive Precipitates In Targeted Cells"
- U.S. Patent No. 6,080,383, issued 06/27/00 in SN 08/782,219, filed 01/13/97, for "A Method And Composition For The Treatment Of Cancer By The Enzymatic Conversion Of Soluble Radioactive Toxic Agents Into Radioactive Toxic Precipitates In The Cancer"
- 3. U.S. CPA, filed 01/19/00, of SN 08/782,589, filed 01/13/97, for "A Method For The Treatment Of Cancer By The Attachment Of Soluble Radioactive Toxic Agents To Non-Toxic Extra-Cellular Precipitates"
- 4. U.S. CPA, filed 11/16/99, of SN 08/782,590, filed 01/13/97, for "A Method And Composition For Treating Cancer By Converting Soluble Radioactive Toxic Agents Into Insoluble Radioactive Toxic Precipitates Via The Action Of Non-Endocytosing Receptors Of Target Cells"
- U.S. Application SN 09/314,422, filed 05/18/00.
   Division of SN 08/782,219, filed 01/13/97,
   for "A Method And Composition For The Treatment Of Soluble Radioactive Precipitates In The Cancer"
- 6. EPO Appln. No. 98902485.6, filed 01/13/98, of PCT/US98/00511, based on U.S. SN 08/782,219, filed 01/13/97, for "A Method And Composition For The Treatment Of Cancer By The Enzymatic Conversion Of Soluble Radioactive Toxic Agents Into Radioactive Toxic Precipitates In The Cancer"
- 7. Japan Application SN 531191/98, filed 07/13/99, of PCT/US98/00511, based on U.S. SN 08/782,219, filed 01/13/97, for "A Method And Composition For The Treatment Of Cancer By The Enzymatic Conversion Of Soluble Radioactive Toxic Agents Into Radioactive Toxic Precipitates In The Cancer"

## POWER OF ATTORNEY

I, Devid Rose, of 55.	52 VALLEJO	STEEET	OKKLAND	<b>८</b> ९
94608 ai	addrous)			

of ONCOLOGIC, INC. of 3065 Richmond Parkway, Suite 57, Richmond, California 94806-5719.

Samuel Rose, M.D. (deceased June 3, 2001), formerly of 4 Commodore Drive, Apartment D-435, Emeryville, California 94608, on December 8, 2000 assigned to Oncologic, Inc., its successors and assigns, the entire right, title, and interest in and to the two (2) U.S. Letters Patent and three (3) Applications for U.S. Letters Patent shown on Schedule A attached. (Copy of said assignment attached.)

I hereby appoint the following attorney to presente the three (3) patent applications shown on Schedulo A and to transact all business in the U.S. Patent and Trademark Office connected with the three (3) patent applications and the two (2) patents shown on Schedule A attached:

John Q. McQuillan, Esq. Rcg. No. 19805 125 Crestwood Avenue Tuckahoe New York 10707-2208

All correspondence should be addressed to said anomey.

David Rose

7 | 50 | 01 | Date

ONCOLOGIC, INC.

Secretary and Tremsurer

## SCHEDULE A

- 1. U.S. Patent No. 5,816,259, issued 10/06/98 in SN 08/782,380, filed 01/13/97, for "A Method For The Diagnosis And Treatment Of Cancer By The Accumulation Of Radioactive Precipitates In Targeted Cells"
- 2. U.S. Patent No. 6,080,383, issued 06/27/00 in SN 08/782,219, filed 01/13/97, for "A Method And Composition For The Treatment Of Cancer By The Enzymatic Conversion Of Soluble Radioactive Toxic Agents Into Radioactive Toxic Precipitates In The Cancer"
- 3. U.S. CPA, filed 01/19/00, of SN 08/782,589, filed 01/13/97, for "A Method For The Treatment Of Cancer By The Attachment Of Soluble Radioactive Toxic Agents To Non-Toxic Extra-Cellular Precipitates"
- 4. U.S. CPA, filed 11/16/99, of SN 08/782,590, filed 01/13/97, for "A Method And Composition For Treating Cancer By Converting Soluble Radioactive Toxic Agents Into Insoluble Radioactive Toxic Precipitates Via The Action Of Non-Endocytosing Receptors Of Target Cells"
- 5. U.S. Application SN 09/314.422, filed 05/18/00.
  Division of SN 08/782,219, filed 01/13/97,
  for "A Method And Composition For The Treatment Of
  Soluble Radioactive Precipitates In The Cancer"